Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindications Updated U.S. label ...
CAMZYOS reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction. Echocardiogram assessments of LVEF are required prior to and during treatment with ...
Positive results support the potential for Camzyos to be the first cardiac myosin inhibitor for the treatment of adolescent oHCM PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (BMY) (NYSE: ...
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Suraxavir marboxil (GP681) is an orally available prodrug that is converted in vivo to the active metabolite GP1707D07, a PA-targeting antiviral against influenza. Because GP1707D07 is primarily ...
Positive results support the potential for Camzyos to be the first cardiac myosin inhibitor for the treatment of adolescent oHCM “The SCOUT-HCM study is important for patients and the field of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results